Chiara Cremolini
基娅拉·克雷莫利尼
MD, PhD
Associate Professor of Medical Oncology, Department of Translational Research转化研究系医学肿瘤学副教授
👥Biography 个人简介
Dr. Chiara Cremolini led the landmark TRIBE and TRIBE2 trials demonstrating superiority of FOLFOXIRI plus bevacizumab in first-line metastatic CRC. Her research defines optimal upfront treatment strategies based on molecular subtypes and clinical risk features.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FOLFOXIRI Triplet Chemotherapy
Led the TRIBE and TRIBE2 phase III trials demonstrating overall survival benefit of FOLFOXIRI plus bevacizumab over FOLFIRI plus bevacizumab in first-line metastatic CRC, establishing the triplet regimen as preferred for fit patients.
Molecular Subtype-Guided Treatment Selection
Pioneered molecular stratification approaches integrating RAS/BRAF status, BRAF subtype, MSI status, and sidedness to personalize first-line treatment selection in metastatic CRC, optimizing benefit-risk across patient subgroups.
Representative Works 代表性著作
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic CRC: TRIBE2 trial
Annals of Oncology (2020)
Phase III TRIBE2 trial confirming OS benefit of upfront FOLFOXIRI + bevacizumab in first-line metastatic CRC.
Optimizing first-line treatment of BRAF V600E-mutant metastatic CRC: insights from molecular stratification
Journal of Clinical Oncology (2023)
Molecular-guided analysis optimizing treatment selection for BRAF-mutant metastatic CRC subgroups.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 基娅拉·克雷莫利尼 的研究动态
Follow Chiara Cremolini's research updates
留下邮箱，当我们发布与 Chiara Cremolini（University of Pisa）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment